Menu

利伐沙班中国价格

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Suitable for adult patients with deep vein thrombosis and non-valvular atrial fibrillation.

The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents.

For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a missed dose occurs, the patient should take rivaroxaban immediately and continue taking the drug once a day the next day. Patients can take rivaroxaban with a meal or on its own.

Rivaroxaban has proven efficacy and is already on the market in China. What is the price of rivaroxaban in China?

Price of rivaroxaban: Domestic rivaroxaban is the original drug produced by Bayer Pharma AG/Germany Bayer Pharmaceuticals. Specification: 10mg-5 tablets/box, priced at about 138$; Specification: 15mg-7 tablets/box, priced at about 199$; Specification: 20mg-7 tablets/box, priced at about 263$.

In addition, there is also a more affordable foreign version:

The specifications of rivaroxaban available abroad are 15mg*28 tablets; the price of 20mg*28 tablets is around $600. For specific prices, please consult Medical Companion Travel.

Rivaroxaban is a highly selective oral drug that directly inhibits factor Xa. By inhibiting factor Xa, it can interrupt the intrinsic and extrinsic pathways of the coagulation cascade and inhibit thrombin generation and thrombosis. Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans.

The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。